Neurogene
NGNE
52 hedge funds and large institutions have $253M invested in Neurogene in 2017 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 6 closing their positions.
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
64% more call options, than puts
Call options by funds: $208K | Put options by funds: $127K
21% more funds holding
Funds holding: 43 → 52 (+9)
0.07% more ownership
Funds ownership: 4.51% → 4.58% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less capital invested
Capital invested by funds: $300M → $253M (-$47.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.81M |
| 2 |
Millennium Management
New York
|
+$1.37M |
| 3 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
+$712K |
| 4 |
EU
Emory University
Atlanta,
Georgia
|
+$552K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$474K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.19M |
| 2 |
Goldman Sachs
New York
|
-$1.78M |
| 3 |
VEA
Virtus ETF Advisers
New York
|
-$339K |
| 4 |
AP
Archon Partners
Princeton Junction,
New Jersey
|
-$268K |
| 5 |
ProShare Advisors
Bethesda,
Maryland
|
-$188K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| $5K | -$63.5K | -271 | -93% |
|
52
Barclays
London,
United Kingdom
| $1K | +$703 | +3 | New |
|
|
VEA
53
Virtus ETF Advisers
New York
| – | -$339K | -1,193 | Closed |
|
|
AP
54
Archon Partners
Princeton Junction,
New Jersey
| – | -$268K | -945 | Closed |
|
|
55
ProShare Advisors
Bethesda,
Maryland
| – | -$188K | -661 | Closed |
|
|
ICOA
56
Investment Centers of America
Bismarck,
North Dakota
| – | -$175K | -617 | Closed |
|
57
Citigroup
New York
| – | -$14K | -50 | Closed |
|
|
AG
58
Advisor Group
Phoenix,
Arizona
| – | -$3K | -10 | Closed |
|
NGNE Hedge Fund Activity: Q4 2017 in Review
52 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q4 2017, worth a combined $253M — down 16% from $300M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new NGNE positions and 6 closed out — a net gain of 9 holders — while 16 added to existing stakes and 9 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $3.81M. The largest seller was BlackRock, cutting an estimated $4.19M.
- 52 institutional investors held Neurogene (NGNE) as of Q4 2017, up from 43 in Q3 2017.
- Funds reported $253M of Neurogene stock for Q4 2017, down 16% quarter-over-quarter.
- 15 funds opened new Neurogene positions in Q4 2017 and 6 closed out, a net change of +9 holders.
- The largest Neurogene buyer in Q4 2017 was Point72 Asset Management, an estimated $3.81M added.
- The largest Neurogene seller in Q4 2017 was BlackRock, an estimated $4.19M sold.
Based on aggregated 13F filings for Q4 2017.